NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
FLUORESCITE (fluorescein sodium) by Alcon is 12. First approved in 2006.
Drug data last refreshed 23h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUORESCITE (fluorescein sodium) is an intravenous diagnostic dye used in fluorescein angiography to visualize retinal and choroidal vasculature during ophthalmologic examination. The drug fluoresces when excited by blue light (465-490 nm wavelengths), emitting yellowish-green light (520-530 nm) that is captured by fundus cameras to demarcate blood vessel patterns. It enables clinicians to detect vascular abnormalities, retinal diseases, and choroidal pathology.
LOE Approaching
Product is approaching loss of exclusivity with low current job market activity; small commercial teams are typical for legacy diagnostic products with stable but limited market.
Mechanism of Action
12.1 Mechanism of Action Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following…
Indications
Worked on FLUORESCITE at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.